- Home
- GOVX vs CDIO Comparison
GOVX vs CDIO Comparison
Compare GOVX & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- CDIO
- Stock Information
- Founded
- GOVX 2001
- CDIO 2017
- Country
- GOVX United States
- CDIO United States
- Employees
- GOVX N/A
- CDIO N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- GOVX Health Care
- CDIO Health Care
- Exchange
- GOVX Nasdaq
- CDIO Nasdaq
- Market Cap
- GOVX 7.6M
- CDIO 6.4M
- IPO Year
- GOVX N/A
- CDIO N/A
- Fundamental
- Price
- GOVX $0.68
- CDIO $3.77
- Analyst Decision
- GOVX Strong Buy
- CDIO
- Analyst Count
- GOVX 3
- CDIO 0
- Target Price
- GOVX $10.67
- CDIO N/A
- AVG Volume (30 Days)
- GOVX 690.2K
- CDIO 23.0K
- Earning Date
- GOVX 11-11-2025
- CDIO 11-12-2025
- Dividend Yield
- GOVX N/A
- CDIO N/A
- EPS Growth
- GOVX N/A
- CDIO N/A
- EPS
- GOVX N/A
- CDIO N/A
- Revenue
- GOVX $6,143,044.00
- CDIO $19,507.00
- Revenue This Year
- GOVX N/A
- CDIO $1,434.82
- Revenue Next Year
- GOVX N/A
- CDIO $4,661.91
- P/E Ratio
- GOVX N/A
- CDIO N/A
- Revenue Growth
- GOVX 1943.07
- CDIO N/A
- 52 Week Low
- GOVX $0.43
- CDIO $3.22
- 52 Week High
- GOVX $3.88
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- GOVX 41.08
- CDIO 48.42
- Support Level
- GOVX $0.65
- CDIO $3.58
- Resistance Level
- GOVX $0.73
- CDIO $3.98
- Average True Range (ATR)
- GOVX 0.04
- CDIO 0.23
- MACD
- GOVX -0.00
- CDIO 0.02
- Stochastic Oscillator
- GOVX 21.28
- CDIO 56.40
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.